HEPATOLOGY: Official journal of AASLD (
@AASLDtweets
) covering liver diseases, hepatitis, cancer, cirrhosis, drug metabolism, and immunology
#AASLDJournals
NEW PRACTICE GUIDANCE!
Singal A et al.
@AASLDtweets
Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
#LiverTwitter
REVIEW: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC
Suzanne Sharpton &
@DrLoomba
#LiverTwitter
🚨
@AASLDtweets
Practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis 🚨 JUST RELEASED
#LiverTwitter
#LiverX
REVIEW: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management
Allaire M & Thabut D.
#LiverTwitter
REVIEW:
Mehta N et al. Refining the approach to down-staging of HCC prior to liver transplantation: Patient selection, loco-regional treatments, and systemic therapies.
#LiverTwitter
🚨
@AASLDtweets
Guía práctica sobre la estratificación del riesgo y el manejo de la hipertensión portal y las várices en la cirrosis 🚨 RECIÉN PUBLICADO
#LiverTwitter
#LiverX
NEW PRACTICE GUIDANCE
A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases
#LiverTwitter
#HEP_highlights
: This new score for at-risk MASH is absolutely MASEF!
The serum-based Metabolomics-Advanced Steatohepatitis Fibrosis (MASEF) score can accurately identify MASH with ≥F2 fibrosis
#LiverTwitter
@NoureddinMD
⭐️HOT OFF THE PRESS⭐️
LEGACY study evaluating response of 90Y glass microspheres for solitary unresectable
#HCC
↪️88.3% response rate
��️62.2% with response for at least 6 months
↪️86.6% 3yr survival
@bostonsci
@AASLDtweets
@riadsalemIR
#livertwitter
👉🏼
PRACTICE GUIDANCE
Schilsky M et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.
#LiverTwitter
#Aspirin
use and risk of
#HCC
in patients with chronic
#hepatitisB
with or without
#cirrhosis
✅Associated with ⬇️ risks of HCC and liver-associated mortality in adults with CHB
✅Cirrhosis status had a substantial effect
#LiverTwitter
#HEP_Highlights
A Right way to TIPS
Bommena S et al. The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study
#LiverTwitter
Huang DQ, Tran A et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase
#LiverTwitter
#HEP_highlights
: Refractory Hepatic Hydrothorax: An Ominous Sign of End-Stage Liver Disease
Chin A et al. Refractory HH is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites
#LiverTwitter
Edeline J et al. Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials
#LiverTwitter
Younossi ZM et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
#LiverTwitter
Díaz-González Á et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
#LiverTwitter
ABIDE score predicts decompensation in
#NAFLD
#cirrhosis
✳️ Uses AST/ALT ratio, bilirubin, INR, DM2, and esophageal varices
✳️ Model constructed and validated in patients with bx proven cirrhosis
✳️ 5y accuracy better than other markers including CTP, MELD
NUEVA GUÍA DE PRÁCTICA CLÍNICA
Un enfoque multidisciplinario para el diagnóstico y tratamiento de la enfermedad de Wilson: Guía práctica de 2022 sobre la enfermedad de Wilson de la AASLD
#LiverTwitter
Lv Y et al. Development and validation of a prognostic score to identify the optimal candidate for preemptive TIPS in patients with cirrhosis and acute variceal bleeding
#LiverTwitter
Congratulations to Dr. David Cohen,
#BrighamGIAlum
, our former Dir. of Hepatology & current Chief of
@WCM_GI
, for his election to the prestigious Association of American Physicians!
Dr. Cohen is a leader in studying the molecular regulation of hepatic lipid & glucose metabolism.
Nicoară-Farcău O et al.
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis
#LiverTwitter
¡NUEVA GUÍA DE PRÁCTICA!
Singal A et al.
@AASLDtweets
Guía práctica sobre prevención, diagnóstico y tratamiento del carcinoma hepatocelular
#LiverTwitter
@AASLDtweets
Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage
Lee EW et al.
#livertwitter
Deltenre P et al. The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions
#LiverTwitter
#HEP_Highlights
But maybe the AlcHep will recompensate… or not?
✅ Hsu C et al. Multi-Centered Study of Patient Outcomes after Declined for Early Liver Transplantation in Severe Alcohol-Associated Hepatitis
#LiverTwitter
Levy C et al. Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
#LiverTwitter
@DrCynthiaLevy
Corpechot C et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
#LiverTwitter
@AASLDtweets
Guía práctica sobre el uso de TIPS, embolización de várices y obliteración transvenosa retrógrada en el tratamiento de la hemorragia de várices
Lee EW et al.
#livertwitter
Phase 2 study by
@DrLoomba
et al: effect of Aldafermin (
#FGF
analog) on
#gut
#microbiota
✳️ Pts with biopsy confirmed
#NASH
+
#fibrosis
+ elevated liver fat
✳️ 12 weeks of drug vs placebo
✳️ Aldafermin cohort had ⬆️Veillonella correlating w/ ⬇️bile acids
Important read for all involved in the care of liver patients!
AASLD expert panel publishes a consensus statement on best practice for hepatologists during
#Covid_19
#HEP_highlights
Itching for Improvement- New Treatment Option for Primary Biliary Cholangitis
🚨Pts w/PBC with inadequate resp or intolerance to UDCA treated with seladelpar 10 mg had significant improve in liver biochemistry and pruritus.
#livertwitter
Genome-wide association study and meta-analysis identifies genetic variants that underlie risk for
#alcohol
-related
#cirrhosis
- see the author’s summary below!
#HEP_highlights
May:
Sanyal A et al. study, based on two large placebo-controlled trials demonstrated that
#regression
of
#NAFLD
cirrhosis is associated with a lower risk of liver-related clinical events
#LiverTwitter
The global burden of liver cancer and
#cirrhosis
has increased from 2012 to 2017 with
#NAFLD
growing as a contributor to liver related morbidity and mortality
Younossi ZM et al. La epidemiología mundial de la enfermedad del hígado graso no alcohólico (NAFLD) y la esteatohepatitis no alcohólica (NASH): una revisión sistemática
#LiverTwitter
Important review on addressing
#NAFLD
in important populations where there can be benefits, impact on future generations and those at high risk for progression
🔑Children and adolescents
🔑Future parents
🔑Postmenopausal women
REVIEW‼️
Friedman S & Sanyal A.
The future of hepatology:
✅Basic and translational science
✅Data management
✅Artificial intelligence
✅Precision medicine
How cool is our December issue cover?! 🤩
We encourage authors to submit original artwork for the journal cover. Congratulations to the authors of our December cover article
#LiverTwitter
@hmalhi
@SumeraIlyasMD
Actionable items for reducing the burden of
#alcohol
associated
#liver
disease by
@AsraniSumeet
et al
🔅Improve data, standardize care
🔅Innovative healthcare delivery platforms
🔅Increase
#advocacy
by professional organizations
🔅Digital interventions
#HEP_highlights
Etiological Treatment of Decompensated Cirrhosis: Is It Worthwhile?
Tonon L, Balcar L et al. In patients with cirrhosis and ascites as single first decompensating event, the cure of liver disease etiology represents a main treatment goal
HEP_Highlights: Short Telomeres, Big Questions
Gellert-Kristensen H et al. Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
#LiverTwitter
#HEP_highlights
January: A picture is worth a thousand words - MRE in NAFLD
Serial MREs used to measure longitudinal liver stiffness show promise in predicting disease progression and liver-related outcomes in pts with NAFLD
@AlinaAllenMD
#livertwitter
#HEP_highlights
To Treat, or Not to Treat
Huang DQ et al. Among pts with compensated cirrhosis and serum HBV-DNA levels 20-2000 IU/mL, treatment with antiviral therapy does not lead to ⬇️ rates of hepatic decompensation or HCC
#LiverTwitter
HEP_highlights November: Precision genomics for unexplained ALT elevation
Alonso-Peña M et al. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
#LiverTwitter
#HEP_Highlights
January: Detection of
#cholangiocarcinoma
in pts with
#PSC
is incredibly challenging. Vedeld et al. identified DNA methylation biomarkers that detected CCA up to 12 months prior to conventional CCA detection modalities.
#LiverTwitter